|
1
|
Kademani D: Oral cancer. Mayo Clin Proc.
82:pp. 878–887. 2007; View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Petersen PE: The World Oral Health Report
2003: Continuous improvement of oral health in the 21st century -
the approach of the WHO Global Oral Health Programme. Community
Dent Oral Epidemiol. 31 Suppl 1:3–23. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lothaire P, de Azambuja E, Dequanter D,
Lalami Y, Sotiriou C, Andry G, Castro G Jr and Awada A: Molecular
markers of head and neck squamous cell carcinoma: Promising signs
in need of prospective evaluation. Head Neck. 28:256–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cecchi F, Rabe DC and Bottaro DP:
Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer.
46:1260–1270. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Birchmeier C, Birchmeier W, Gherardi E and
Woude GF Vande: Met, metastasis, motility and more. Nat Rev Mol
Cell Biol. 4:915–925. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Trusolino L and Comoglio PM:
Scatter-factor and semaphorin receptors: Cell signalling for
invasive growth. Nat Rev Cancer. 2:289–300. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maulik G, Shrikhande A, Kijima T, Ma PC,
Morrison PT and Salgia R: Role of the hepatocyte growth factor
receptor, c-Met, in oncogenesis and potential for therapeutic
inhibition. Cytokine Growth Factor Rev. 13:41–59. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Laterra J, Nam M, Rosen E, Rao JS, Lamszus
K, Goldberg ID and Johnston P: Scatter factor/hepatocyte growth
factor gene transfer enhances glioma growth and angiogenesis in
vivo. Lab Invest. 76:565–577. 1997.PubMed/NCBI
|
|
10
|
Mhawech-Fauceglia P, Afkhami M and Pejovic
T: MET/HGF signaling pathway in ovarian carcinoma: Clinical
implications and future direction. Pathol Res Int. 2012:9603272012.
View Article : Google Scholar
|
|
11
|
Chu JS, Ge FJ, Zhang B, Wang Y, Silvestris
N, Liu LJ, Zhao CH, Lin L, Brunetti AE, Fu YL, et al: Expression
and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced
hepatocellular carcinoma. J Exp Clin Cancer Res. 32:16–23. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Landi L, Minuti G, D'Incecco A and
Cappuzzo F: Targeting c-MET in the battle against advanced
nonsmall-cell lung cancer. Curr Opin Oncol. 25:130–136. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li C, Wu JJ, Hynes M, Dosch J, Sarkar B,
Welling TH, di Magliano M Pasca and Simeone DM: c-Met is a marker
of pancreatic cancer stem cells and therapeutic target.
Gastroenterology. 141:2218–2227.e5. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Herreros-Villanueva M, Zubia-Olascoaga A
and Bujanda L: c-Met in pancreatic cancer stem cells: Therapeutic
implications. World J Gastroenterol. 18:5321–5323. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu Y, Liu JH, Chai K, Tashiro S, Onodera
S and Ikejima T: Inhibition of c-Met promoted apoptosis, autophagy
and loss of the mitochondrial transmembrane potential in
oridonin-induced A549 lung cancer cells. J Pharm Pharmacol.
65:1622–1642. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun Z, Hu S, Luo Q, Ye D, Hu D and Chen F:
Overexpression of SENP3 in oral squamous cell carcinoma and its
association with differentiation. Oncol Rep. 29:1701–1706. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Perera T, Lavrijssen T, Janssens B, Geerts
T, King P, Mevellec L, Cummings M, Lu T, Johnson D and Page M:
JNJ-38877605: A selective Met kinase inhibitor inducing regression
of Met-driven tumor models. Presented at the 99th AACR Annual
Meeting. Apr 12–16, 2008; San Diego, CA, USA. pp. 4837
|
|
18
|
Torti D, Sassi F, Galimi F, Gastaldi S,
Perera T, Comoglio PM, Trusolino L and Bertotti A: A preclinical
algorithm of soluble surrogate biomarkers that correlate with
therapeutic inhibition of the MET oncogene in gastric tumors. Int J
Cancer. 130:1357–1366. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Weiner D, Khankin EV, Levy Y and Reznick
AZ: Effects of cigarette smoke borne reactive nitrogen species on
salivary alpha-amylase activity and protein modifications. J
Physiol Pharmacol. 60 Suppl 5:127–132. 2009.PubMed/NCBI
|
|
20
|
Wald NJ and Hackshaw AK: Cigarette
smoking: An epidemiological overview. Br Med Bull. 52:3–11. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kłosek SK, Sporny S, Stasikowska-Kanicka O
and Kurnatowska AJ: Cigarette smoking induces overexpression of
c-Met receptor in microvessels of oral lichen planus. Arch Med Sci.
7:706–712. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen JT, Lin TS, Chow KC, Huang HH, Chiou
SH, Chiang SF, Chen HC, Chuang TL, Lin TY and Chen CY: Cigarette
smoking induces overexpression of hepatocyte growth factor in type
II pneumocytes and lung cancer cells. Am J Respir Cell Mol Biol.
34:264–273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yoneyama R, Aoshiba K, Furukawa K, Saito
M, Kataba H, Nakamura H and Ikeda N: Nicotine enhances hepatocyte
growth factor-mediated lung cancer cell migration by activating the
α7 nicotine acetylcholine receptor and phosphoinositide
kinase-3-dependent pathway. Oncol Lett. 11:673–677. 2016.PubMed/NCBI
|
|
24
|
Sun S and Wang Z: Head neck squamous cell
carcinoma c-Met+ cells display cancer stem cell properties and are
responsible for cisplatin-resistance and metastasis. Int J Cancer.
129:2337–2348. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Seiwert TY, Jagadeeswaran R, Faoro L,
Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen
EE, Lingen MW, et al: The MET receptor tyrosine kinase is a
potential novel therapeutic target for head and neck squamous cell
carcinoma. Cancer Res. 69:3021–3031. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
De Herdt MJ and de Jong RJ Baatenburg: HGF
and c-MET as potential orchestrators of invasive growth in head and
neck squamous cell carcinoma. Front Biosci. 13:2516–2526. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Freudlsperger C, Alexander D, Reinert S
and Hoffmann J: Prognostic value of c-Met expression in oral
squamous cell carcinoma. Exp Ther Med. 1:69–72. 2010.PubMed/NCBI
|
|
28
|
Hanzawa M, Shindoh M, Higashino F, Yasuda
M, Inoue N, Hida K, Ono M, Kohgo T, Nakamura M, Notani K, et al:
Hepatocyte growth factor upregulates E1AF that induces oral
squamous cell carcinoma cell invasion by activating matrix
metalloproteinase genes. Carcinogenesis. 21:1079–1085. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Murai M, Shen X, Huang L, Carpenter WM,
Lin CS, Silverman S, Regezi J and Kramer RH: Overexpression of
c-met in oral SCC promotes hepatocyte growth factor-induced
disruption of cadherin junctions and invasion. Int J Oncol.
25:831–840. 2004.PubMed/NCBI
|
|
30
|
Kim CH, Koh YW, Han JH, Kim JW, Lee JS,
Baek SJ, Hwang HS and Choi EC: c-Met expression as an indicator of
survival outcome in patients with oral tongue carcinoma. Head Neck.
32:1655–1664. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lim YC, Kang HJ and Moon JH: C-Met pathway
promotes self-renewal and tumorigenecity of head and neck squamous
cell carcinoma stem-like cell. Oral Oncol. 50:633–639. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hartmann S, Bhola NE and Grandis JR:
HGF/Met signaling in head and neck cancer: Impact on the tumor
microenvironment. Clin Cancer Res. 22:4005–4013. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lim YC, Han JH, Kang HJ, Kim YS, Lee BH,
Choi EC and Kim CH: Overexpression of c-Met promotes invasion and
metastasis of small oral tongue carcinoma. Oral Oncol.
48:1114–1119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tao X, Hill KS, Gaziova I, Sastry SK, Qui
S, Szaniszlo P, Fennewald S, Resto VA and Elferink LA: Silencing
Met receptor tyrosine kinase signaling decreased oral tumor growth
and increased survival of nude mice. Oral Oncol. 50:104–112. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yao HP, Zhou YQ, Zhang R and Wang MH:
MSP-RON signalling in cancer: Pathogenesis and therapeutic
potential. Nat Rev Cancer. 13:466–481. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ma PC, Tretiakova MS, Nallasura V,
Jagadeeswaran R, Husain AN and Salgia R: Downstream signalling and
specific inhibition of c-MET/HGF pathway in small cell lung cancer:
Implications for tumour invasion. Br J Cancer. 97:368–377. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu X, Newton RC and Scherle PA:
Developing c-MET pathway inhibitors for cancer therapy: Progress
and challenges. Trends Mol Med. 16:37–45. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Matsumoto K and Nakamura T: Hepatocyte
growth factor and the Met system as a mediator of tumor-stromal
interactions. Int J Cancer. 119:477–483. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
You WK and McDonald DM: The hepatocyte
growth factor/c-Met signaling pathway as a therapeutic target to
inhibit angiogenesis. BMB Rep. 41:833–839. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zeng Q, Chen S, You Z, Yang F, Carey TE,
Saims D and Wang CY: Hepatocyte growth factor inhibits anoikis in
head and neck squamous cell carcinoma cells by activation of ERK
and Akt signaling independent of NFkappa B. J Biol Chem.
277:25203–25208. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zeng Q, McCauley LK and Wang CY:
Hepatocyte growth factor inhibits anoikis by induction of activator
protein 1-dependent cyclooxygenase-2. Implication in head and neck
squamous cell carcinoma progression. J Biol Chem. 277:50137–50142.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Rosen EM and Goldberg ID: Scatter factor
and angiogenesis. Adv Cancer Res. 67:257–279. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC
and Van Waes C: Hepatocyte growth factor/scatter factor-induced
activation of MEK and PI3K signal pathways contributes to
expression of proangiogenic cytokines interleukin-8 and vascular
endothelial growth factor in head and neck squamous cell carcinoma.
Cancer Res. 61:5911–5918. 2001.PubMed/NCBI
|
|
44
|
Michi Y, Morita I, Amagasa T and Murota S:
Human oral squamous cell carcinoma cell lines promote angiogenesis
via expression of vascular endothelial growth factor and
upregulation of KDR/flk-1 expression in endothelial cells. Oral
Oncol. 36:81–88. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sequist LV, von Pawel J, Garmey EG,
Akerley WL, Brugger W, Ferrari D, Chen Y, Costa DB, Gerber DE,
Orlov S, et al: Randomized phase II study of erlotinib plus
tivantinib versus erlotinib plus placebo in previously treated
non-small-cell lung cancer. J Clin Oncol. 29:3307–3315. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Smith DC, Smith MR, Sweeney C, Elfiky AA,
Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon
MS, et al: Cabozantinib in patients with advanced prostate cancer:
Results of a phase II randomized discontinuation trial. J Clin
Oncol. 31:412–419. 2013. View Article : Google Scholar : PubMed/NCBI
|
